Telix Pharmaceuticals is trading at A$13.94, up +4.65%, amid an active biotech-sector rally; no source explicitly links the move to a company announcement.
- Telix held its Capital Markets Day on November 4, outlining its growth strategy, pipeline and planned ITM integration.
- Coverage highlighted a target to transition toward earnings growth from 2028; Telix’s listed presentation confirms the event.